Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
46
MOLN Quote, Financials, Valuation and Earnings
Last price:
$4.33
Seasonality move
:
28.84%
Day range:
$4.30 - $4.36
52-week range:
$3.36 - $5.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
187.52x
P/B ratio:
1.36x
Volume:
1.3K
Avg. volume:
3.6K
1-year change:
-8.2%
Market cap:
$163M
Revenue:
$5.6M
EPS (TTM):
-$1.91
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MOLN
Molecular Partners AG
|
-- | -$0.35 | -100% | -0.76% | $10.63 |
|
ACIU
AC Immune SA
|
$1.5M | -$0.19 | 18.61% | -6.92% | $9.01 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$3.9M | -$1.23 | -89.16% | -180.62% | $81.33 |
|
ONC
BeOne Medicines Ltd.
|
$1.5B | $1.42 | 29.38% | -70.04% | $400.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MOLN
Molecular Partners AG
|
$4.36 | $10.63 | $163M | -- | $0.00 | 0% | 187.52x |
|
ACIU
AC Immune SA
|
$3.14 | $9.01 | $315.9M | -- | $0.00 | 0% | 61.23x |
|
ADXN
Addex Therapeutics Ltd.
|
$7.72 | $30.00 | $9.5M | 0.77x | $0.00 | 0% | 35.31x |
|
CRSP
CRISPR Therapeutics AG
|
$52.44 | $81.33 | $5B | -- | $0.00 | 0% | 119.61x |
|
ONC
BeOne Medicines Ltd.
|
$303.81 | $400.06 | $33.6B | 584.59x | $0.00 | 0% | 6.79x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MOLN
Molecular Partners AG
|
1.58% | 1.256 | 1.39% | 9.08x |
|
ACIU
AC Immune SA
|
6.95% | 3.658 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 1.731 | 0.5% | 1.91x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 2.726 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | -0.083 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MOLN
Molecular Partners AG
|
-$658.5K | -$14.9M | -48.43% | -49.28% | -2407.93% | -$12.8M |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Molecular Partners AG vs. Competitors
-
Which has Higher Returns MOLN or ACIU?
AC Immune SA has a net margin of -2408.81% compared to Molecular Partners AG's net margin of -1688.87%. Molecular Partners AG's return on equity of -49.28% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital MOLNMolecular Partners AG-- -$0.40 $122M ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About MOLN or ACIU?
Molecular Partners AG has a consensus price target of $10.63, signalling upside risk potential of 143.87%. On the other hand AC Immune SA has an analysts' consensus of $9.01 which suggests that it could grow by 187.31%. Given that AC Immune SA has higher upside potential than Molecular Partners AG, analysts believe AC Immune SA is more attractive than Molecular Partners AG.
Company Buy Ratings Hold Ratings Sell Ratings MOLNMolecular Partners AG3 1 0 ACIUAC Immune SA4 0 0 -
Is MOLN or ACIU More Risky?
Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.623, suggesting its more volatile than the S&P 500 by 62.312%.
-
Which is a Better Dividend Stock MOLN or ACIU?
Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MOLN or ACIU?
Molecular Partners AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Molecular Partners AG's net income of -$14.8M is higher than AC Immune SA's net income of -$19.8M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 187.52x versus 61.23x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MOLNMolecular Partners AG187.52x -- -- -$14.8M ACIUAC Immune SA61.23x -- $1.2M -$19.8M
-
Which has Higher Returns MOLN or ADXN?
Addex Therapeutics Ltd. has a net margin of -2408.81% compared to Molecular Partners AG's net margin of -3178.71%. Molecular Partners AG's return on equity of -49.28% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital MOLNMolecular Partners AG-- -$0.40 $122M ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About MOLN or ADXN?
Molecular Partners AG has a consensus price target of $10.63, signalling upside risk potential of 143.87%. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 288.6%. Given that Addex Therapeutics Ltd. has higher upside potential than Molecular Partners AG, analysts believe Addex Therapeutics Ltd. is more attractive than Molecular Partners AG.
Company Buy Ratings Hold Ratings Sell Ratings MOLNMolecular Partners AG3 1 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is MOLN or ADXN More Risky?
Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.487, suggesting its more volatile than the S&P 500 by 48.685%.
-
Which is a Better Dividend Stock MOLN or ADXN?
Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MOLN or ADXN?
Molecular Partners AG quarterly revenues are --, which are smaller than Addex Therapeutics Ltd. quarterly revenues of $62K. Molecular Partners AG's net income of -$14.8M is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 187.52x versus 35.31x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MOLNMolecular Partners AG187.52x -- -- -$14.8M ADXNAddex Therapeutics Ltd.35.31x 0.77x $62K -$2M
-
Which has Higher Returns MOLN or CRSP?
CRISPR Therapeutics AG has a net margin of -2408.81% compared to Molecular Partners AG's net margin of -11973.12%. Molecular Partners AG's return on equity of -49.28% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital MOLNMolecular Partners AG-- -$0.40 $122M CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About MOLN or CRSP?
Molecular Partners AG has a consensus price target of $10.63, signalling upside risk potential of 143.87%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 55.1%. Given that Molecular Partners AG has higher upside potential than CRISPR Therapeutics AG, analysts believe Molecular Partners AG is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings MOLNMolecular Partners AG3 1 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is MOLN or CRSP More Risky?
Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.700, suggesting its more volatile than the S&P 500 by 69.984%.
-
Which is a Better Dividend Stock MOLN or CRSP?
Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MOLN or CRSP?
Molecular Partners AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Molecular Partners AG's net income of -$14.8M is higher than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 187.52x versus 119.61x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MOLNMolecular Partners AG187.52x -- -- -$14.8M CRSPCRISPR Therapeutics AG119.61x -- $889K -$106.4M
-
Which has Higher Returns MOLN or ONC?
BeOne Medicines Ltd. has a net margin of -2408.81% compared to Molecular Partners AG's net margin of 8.84%. Molecular Partners AG's return on equity of -49.28% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital MOLNMolecular Partners AG-- -$0.40 $122M ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About MOLN or ONC?
Molecular Partners AG has a consensus price target of $10.63, signalling upside risk potential of 143.87%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $400.06 which suggests that it could grow by 31.68%. Given that Molecular Partners AG has higher upside potential than BeOne Medicines Ltd., analysts believe Molecular Partners AG is more attractive than BeOne Medicines Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MOLNMolecular Partners AG3 1 0 ONCBeOne Medicines Ltd.18 1 1 -
Is MOLN or ONC More Risky?
Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.467, suggesting its less volatile than the S&P 500 by 53.26%.
-
Which is a Better Dividend Stock MOLN or ONC?
Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MOLN or ONC?
Molecular Partners AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Molecular Partners AG's net income of -$14.8M is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 584.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 187.52x versus 6.79x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MOLNMolecular Partners AG187.52x -- -- -$14.8M ONCBeOne Medicines Ltd.6.79x 584.59x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
